Navigation Links
Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
Date:1/22/2008

Contracts Give Access to Diagnostic Application of Research Technologies

FULLERTON, Calif., Jan. 22 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC) announced today that it has signed four agreements with National University of Ireland, Galway (NUI Galway) to direct assay research and acquire licenses for intellectual property that will enable development of infectious disease tests for the company's future molecular diagnostic instrument. Under the terms of the three-to-five year agreements, research will begin in early 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

"With these agreements, we will take a big step toward the launch of our 'sample-to-result' molecular diagnostic system, including a differentiated menu of moderately complex tests that address urgent clinical decisions," commented Mike Whelan, group vice president of Beckman Coulter's High Sensitivity Testing Group. "The agreements give us access to intellectual property for the development of tests for infectious diseases including sepsis; hospital-acquired infections; and sexually transmitted diseases, such as Chlamydia and Neisseria." Infectious disease testing comprises about 50 percent of the $2 billion molecular diagnostics market in the United States.

The assay development research relies on NUI Galway nucleic acid detection technology for both bacterial and fungal targets along with SPRI(R) (Solid Phase Reversible Immobilization) and other technologies from Beckman Coulter.

Whelan added, "The combination of NUI Galway technologies with ours gives us a glimpse of the next generation of molecular diagnostics. Our goal is that our simplified, automated solution will allow these time-consuming, complex, and labor-intensive tests to migrate into the routine hospital lab. So physicians will get diagnostic information within hours, instead of days or weeks, and be able to begin treating patients much sooner."

Welcoming this new partnership with Beckman Coulter, Dr. Iognaid O Muircheartaigh, NUI Galway president, praised the work of the researchers leading this initiative. "These leading-edge researchers are addressing some of the most challenging and important issues at the frontier of modern biomedical research -- with the ultimate goal of changing the way patients are diagnosed. The research and technology development collaboration with Beckman Coulter is a strong endorsement from industry of the quality and importance of the research being undertaken at NUI Galway."

"We are excited to partner with Beckman Coulter on this unique initiative," said Dr. Daniel O'Mahony, director, Technology Transfer at NUI Galway. "It underpins our commitment to, and support of, research excellence and exemplifies our stated research strategy: creating an environment that values intellectual property, and promoting technology transfer and commercialization activity among University researchers and industry partners. This collaboration brings together molecular diagnostic expertise at NUI Galway with automated solution expertise at Beckman Coulter that will result in the development of break-through technologies for the diagnosis of a variety of infectious diseases in humans."

Established in 1845 as Queen's College Galway, National University of Ireland, Galway is one of Ireland's foremost centers of academic excellence. With more than 15,000 students, it has a long-established reputation of teaching and research excellence in each of its six colleges -- Arts, Social Sciences and Celtic Studies; Science; Law; Commerce; Engineering and Informatics; Medicine, Nursing and Health Sciences.

Beckman Coulter, Inc., based in Fullerton, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represents more than 75 percent of the company's 2006 annual revenue of $2.53 billion.
For more information, visit http://www.beckmancoulter.com.

Contacts: Mary Luthy

Corporate Communications, Beckman Coulter

Phone: (714) 993-8770

E-mail: mluthy@beckman.com

Allan Harris

Investor Relations, Beckman Coulter

Phone: (714) 773-7620

E-mail: adharris@beckman.com


'/>"/>
SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... N.Y. , Feb. 5, 2016  Henry Schein, ... health care products and services to office-based dental, animal ... entered into an agreement to acquire a majority ownership ... supplies and equipment in Brazil . ... Headquartered in Blumenau, Brazil, Dental Cremer is the dental distribution ...
(Date:2/4/2016)... For hospitals considering enrollment in the Federal ... the program, the Health Resources and Services Administration,s (HRSA) ... Mega-Guidance , could have significant impact on plans and ... 2016. Essential Insights , Daniel Neal, ... the Mega-Guidance,s key proposed changes, including a new requirement ...
(Date:2/4/2016)... 4, 2016   Bernstein Liebhard LLP today announced ... United States District Court for the District of ... consisting of all persons or entities who purchased common shares ... INSY ) from March 3, 2015 through January 25, 2016 ... its officers with violations of the Securities Exchange Act of ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... US Sports Camps , official operators of Nike ... high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in the picturesque New ... ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled to be ...
(Date:2/5/2016)... ... , ... Give To Cure today announced that it is working ... To Cure’s campaign that is crowdfunding clinical trials to help find cures faster for ... a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... in need. The event is scheduled to take place on February 27, 2016 from ... dental care to community members in need. Each patient will be given the opportunity ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of ... A hallmark feature of patients with eating disorders is significant self-criticism, and consequently these ... and obsessions are regarded as maladaptive means for coping with this unease, but also ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Calls Blacklist has ... completely new user interface design and the developer has fixed known bugs within the ... want to on their phone while not consuming any of their device’s battery power ...
Breaking Medicine News(10 mins):